#ArrowheadPharma
LightNews LightNews
theminingnews.bsky.social
🚀 Zacks Small Cap Research - ARWR: SHASTA-3 and SHASTA-4 Data Presented at ESC 2026
🔎 Read the full update:
➡️https://theminingnews.com/zacks-small-cap-research-arwr-shasta-3-and-shasta-4-data-presented-at-esc-2026/
#ARWR #Arr#ARWRd#ArrowheadPharmaa#Plozasiran##SHASTA3##SHASTA4##ESC2026g#Hypertrigly
September 8, 2026 at 3:19 PM
pharmaphorum.bsky.social
#ArrowheadPharma is squaring up to rival #Ionis in the severe hypertriglyceridaemia (sHTG) market, drawing on phase 3 data at #ESC2026.
ESC26: Can Arrowhead pierce Ionis' triglyceride armour?
Arrowhead Pharma is squaring up to rival Ionis in the severe hypertriglyceridaemia (sHTG) market, drawing on phase 3 data at ESC 2026.
pharmaphorum.com
August 31, 2026 at 6:37 PM
theminingnews.bsky.social
🚀 Zacks Small Cap Research - ARWR: Acquires PRV for sNDA Submission for Plozasiran in sHTG
🔎 Read the full update:
➡️https://theminingnews.com/zacks-small-cap-research-arwr-acquires-prv-for-snda-submission-for-plozasiran-in-shtg/
#Arrowhead#ArrowheadPharmao#ARWRa#PlozasiranD#sHTGV#sNDAR#PRVa href="/hashtag/FDARevi" class="hover:underline text-blue-600 dark:text-sky-400 no-card-link">#FDARevi
August 5, 2026 at 8:45 PM
livermd.bsky.social
@HepDART dr. Bruce Given: #HBV RNAi JNJ-3989 can achieve powerful HBsAg reduction across all genotypes & seems well tolerated. Probably need long term combo rx to achieve functional cure @ArrowheadPharma #HEPDART
December 3, 2024 at 2:40 AM
livermd.bsky.social
@HepDART @ArrowheadPharma dr. Given’s candid take on what we don’t know yet re: how to achieve #HBV functional cure
December 3, 2024 at 2:40 AM
markfortner.bsky.social
#Sarepta #ArrowheadPharma
Sarepta pays $500M cash for rights to 'multiple potential blockbusters' from Arrowhead
Sarepta Therapeutics is paying Arrowhead Pharmaceuticals $500 million in cash, plus a $325 million equity investment, for worldwide licensing rights to seven programs—four clinical and three precli | ...
www.fiercebiotech.com
December 4, 2024 at 4:19 PM
dengyuemedicine.bsky.social
La NMPA de China aprueba la comercialización de la inyección de plozasiran sódico

📩 info@dengyuemed.com
🔗https://dengyuepharma.com

#Salud #Farmacéutica #InnovaciónMédica #Triglicéridos #FCS #ArrowheadPharma #NMPA
January 9, 2026 at 8:13 AM
pharmaphorum.bsky.social
The importance of #China as a growth market for #pharma multinationals is underlined by the news that #Sanofi has paid $130 million upfront for Chinese rights to an #ArrowheadPharma drug under review for a disease associated with elevated #triglyceridelevels.

pharmaphorum.com/news/sanofi-...
Sanofi grabs Chinese rights to Arrowhead rare disease drug
Sanofi has paid $130 million upfront for Chinese rights to an Arrowhead Pharma drug for rare disease familial chylomicronaemia syndrome.
pharmaphorum.com
August 4, 2025 at 9:10 AM
anikasharmavibe.bsky.social
Novartis Commits up to $2.2B Toward Developing Arrowhead siRNA Therapy
@Novartis
agreed to license and develop
@ArrowheadPharma
’s preclinical stage siRNA therapy ARO-SNCA, a potential treatment for #Parkinsonsdisease and other synucleinopathies
September 8, 2025 at 7:34 PM